Genor Biopharma Holdings (FRA:67N0) Shares Outstanding (EOP): 521.72 Mil (As of Jun. 2025)


FRA:67N0 Genor Biopharma Holdings Ltd FRA:67N0
22 GF Score
Price €0.34
! 1 Warning Sign
View Full Analysis

What is Genor Biopharma Holdings Shares Outstanding (EOP)?

Genor Biopharma Holdings FRA:67N0 +3.70% 22 Shares Outstanding (EOP) is 521.72 Mil as of Jun. 2025. GuruFocus rates FRA:67N0 with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Genor Biopharma Holdings's shares outstanding for the quarter that ended in Jun. 2025 was 521.72 Mil.

Genor Biopharma Holdings's quarterly shares outstanding increased from Dec. 2024 (516.82 Mil) to Jun. 2025 (521.72 Mil). It means Genor Biopharma Holdings issued new shares from Dec. 2024 to Jun. 2025 .

Genor Biopharma Holdings's annual shares outstanding increased from Dec. 2023 (503.73 Mil) to Dec. 2024 (516.82 Mil). It means Genor Biopharma Holdings issued new shares from Dec. 2023 to Dec. 2024 .


Genor Biopharma Holdings  (FRA:67N0) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Genor Biopharma Holdings Shares Outstanding (EOP) Related Terms


Genor Biopharma Holdings Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Genor Biopharma Holdings's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genor Biopharma Holdings Shares Outstanding (EOP) Chart

Genor Biopharma Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shares Outstanding (EOP)
Get a 7-Day Free Trial 491.03 502.47 501.46 503.73 516.82

Genor Biopharma Holdings Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 502.46 503.73 510.28 516.82 521.72

FRA:67N0 vs VRTX, REGN, ALNY: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Genor Biopharma Holdings's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genor Biopharma Holdings Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genor Biopharma Holdings's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Genor Biopharma Holdings's Shares Outstanding (EOP) falls into.


FRA:67N0
22GF Score
Genor Biopharma Holdings Ltd FRA:67N0
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genor Biopharma Holdings Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 521.72 Mil mean?
Genor Biopharma Holdings (FRA:67N0) has a Shares Outstanding (EOP) of 521.72 Mil as of Jun. 2025. The total shares a company has outstanding, at period-end. View historical data on Genor Biopharma Holdings and its competitors.
Is Genor Biopharma Holdings' Shares Outstanding (EOP) too high?
Genor Biopharma Holdings' current Shares Outstanding (EOP) is 521.72 Mil. Overall, Genor Biopharma Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Genor Biopharma Holdings' Shares Outstanding (EOP) compare to VRTX and REGN?
Genor Biopharma Holdings' Shares Outstanding (EOP) of 521.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Genor Biopharma Holdings and its competitors. Genor Biopharma Holdings's current Shares Outstanding (EOP) is 521.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genor Biopharma Holdings stock overvalued right now?
Genor Biopharma Holdings (FRA:67N0) has a current Shares Outstanding (EOP) of 521.72 Mil. The current Shares Outstanding (EOP) is 521.72 Mil. Genor Biopharma Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Genor Biopharma Holdings (FRA:67N0), the current Shares Outstanding (EOP) is 521.72 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genor Biopharma Holdings Business Description

Address 690 Bibo Road, Room 501-02, Building 6, Pudong New District, Shanghai, CHN, 201203
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates includes GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
22GF Score

Get the complete analysis for FRA:67N0

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.34
Price